American Journal of Ophthalmology
Volume 141, Issue 6 , Pages 997-1008.e3 , June 2006

Management of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study

  • Steven M. Kymes, PhD

      Affiliations

    • Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri
    • Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri
    • Corresponding Author InformationInquiries to Steven M. Kymes, PhD, Washington University School of Medicine, Department of Ophthalmology and Visual Sciences, 660 South Euclid, Campus Box 8096, St Louis, MO 63110-1093
    • ,
  • Michael A. Kass, MD

      Affiliations

    • Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri
    • ,
  • Douglas R. Anderson, MD

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • J. Philip Miller, AB

      Affiliations

    • Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri
    • ,
  • Mae O. Gordon, PhD

      Affiliations

    • Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri
    • Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri
    • ,
  • Ocular Hypertension Treatment Study Group (OHTS)

,Accepted 5 January 2006.

References 

  1. Lighthouse International. New approach to assessing glaucoma risk may help physicians decide who needs treatment: vision connections, 2005. Last accessed: December 15, 2005. Available at: http://www.visionconnection.org/Content/ForProfessionals/PatientManagement/DiseaseManagement/Glaucoma/default.htm
  2. Friedman DS , Congdon N , Kempen J , Tielsch JM . Vision problems in the United States . Washington, DC: National Eye Institute; 2002; Last accessed: December 15, 2005. Available at: http://www.nei.nih.gov/eyedata/pdf/VPUS.pdf
  3. Sommer A , Tielsch JM , Katz J , et al.   Racial differences in the cause-specific prevalence of blindness in east Baltimore . N Engl J Med . 1991;325:1412–1417
  4. Leske MC . The epidemiology of open-angle glaucoma . Am J Epidemiol . 1983;118:166–191
  5. Gordon MO , Beiser JA , Brandt JD , et al.   The Ocular Hypertension Treatment Study (baseline factors that predict the onset of primary open-angle glaucoma) . Arch Ophthalmol . 2002;120:714–720
  6. Varma R , Ying-Lai M , Francis BA , et al.   Prevalence of open-angle glaucoma and ocular hypertension in Latinos (The Los Angeles Latino Eye Study) . Ophthalmology . 2004;111:1439–1448
  7. Eddy DM . Practice policies and guidelines (Where do they come from?) . In:  Burns Joseph E editors. Clinical decision making (from theory to practice) . Sudbury (MA): Jones and Bartlett; 1996;p. 26–33
  8. Kass MA , Heuer DK , Higgenbotham EJ , et al.   The Ocular Hypertension Treatment Study (a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma) . Arch Ophthalmol . 2002;120:701–713
  9. Robin AL , Frick KD , Katz J , Budenz D , Tielsch JM . The Ocular Hypertension Treatment Study (Intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease?) . Arch Ophthalmol . 2004;122:376–378
  10. Jampel HD . Glaucoma patients’ assessment of their visual function and quality of life . Trans Am Ophthalmol Soc . 2001;99:301–317
  11. Parrish RK , Gedde SJ , Scott IU , et al.   Visual function and quality of life among persons with glaucoma . Arch Ophthalmol . 1997;115:1447–1455
  12. Drummond MF , O’Brien B , Stoddart GL , Torrance GW . In: Methods for the economic evaluation of health care programmes . 2nd ed.. Oxford, UK: Oxford University Press; 1997;p. 305
  13. Gordon MO , Kass MA . The Ocular Hypertension Treatment Study (design and baseline description of the participants) . Arch Ophthalmol . 1999;117:573–583
  14. Lee PP , Walt J , Doyle JJ , et al.   A multi-center, retrospective pilot study of resource utilization and costs associated with severity of disease in glaucoma . Arch Ophthalmol . 2006;124:12–19
  15. Hodapp E , Parrish RK , Anderson DR . Clinical decisions in glaucoma . St Louis: Mosby; 1993;
  16. Beck JR , Pauker SG . The Markov process in medical prognosis . Med Decis Making . 1983;3:419–458
  17. Dielemans I , Vingerling JR , Wolfs RCW , Hofman A , Grobbee DE , de Jong PTVM . The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands (The Rotterdam Study) . Ophthalmology . 1994;101:1851–1855
  18. In: Medical Economics Staff, editors. 2005 Drug topics red book. Montvale (NJ): Thomson Medical Economics; 2005.
  19. Meads C , Hyde C . What is the cost of blindness? . Br J Ophthalmol . 2003;87:1201–1204
  20. Clancy CM , Eisenberg JM . Outcomes research (measuring the end results of care) . Science . 1998;282:245–246
  21. Tsevat J . What do utilities measure? . Med Care . 2000;38:S160–S164
  22. Brown GC , Sharma S , Brown MM , Kistler J . Utility values and age-related macular degeneration . Arch Ophthalmol . 2000;118:47–51
  23. Jampel HD , Schwartz A , Pollack I , Abrams D , Weiss H , Miller R . Glaucoma patients’ assessment of their visual function and quality of life . J Glaucoma . 2002;11:154–163
  24. Rabin R , de Charro F . EQ-5D (a measure of health status from the EuroQol Group) . Ann Med . 2001;33:337–343
  25. Kymes SM , Frick KD . Value based medicine (let’s get it right) . [letter] Br J Ophthalmol . 2005;89:643–644
  26. Brown MM , Brown GC , Sharma S , Kistler J , Brown H . Utility values associated with blindness in an adult population . Br J Ophthalmol . 2001;85:327–331
  27. Ubel PA , Hirth RA , Chernew ME , Fendrick AM . What Is the Price of Life and Why Doesn’t It Increase with the Rate of Inflation? . Arch Intern Med . 2003;163:1637–1641
  28. Gillick MR . Medicare coverage for technological innovations (Time for new criteria?) . N Engl J Med . 2004;350:2199–2203
  29. Gold MR , Siegel JE , Russell LB , Weinstein MC . In: Cost-effectiveness in health and medicine . New York: Oxford University Press; 1996;p. 425
  30. Busbee BG , Brown MM , Brown GC , Sharma S . Cost-utility analysis of cataract surgery in the second eye . Ophthalmology . 2003;110:2310–2317
  31. Weinstein MC , O’Brien B , Hornberger J , et al.   Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices: modeling studies . Value Health . 2003;6:9–17
  32. Doubilet P , Begg CB , Weinstein MC , Braun P , McNeil BJ . Probabilistic sensitivity analysis using Monte Carlo simulation . Med Decis Making . 1985;5:157–177
  33. Leske MC , Wu S-Y , Nemesure B , Hennis A . Risk factors for incident nuclear opacities . Ophthalmology . 2002;109:1303–1308
  34. Heijl A , Leske MC , Bengtsson B , Hyman L , Bengtsson B , Hussein M . Reduction of intraocular pressure and glaucoma progression . Arch Ophthalmol . 2002;120:1268–1279
  35. Stinnett AA , Mullahy J . Net health benefits (a new framework for the analysis of uncertainty in cost-effectiveness analysis) . Med Decis Making . 1998;18:S68–S80
  36. Fenwick E , Claxton K , Sculpher M . Representing uncertainty (the role of cost-effectiveness acceptability curves) . Health Econ . 2001;10:779–787
  37. Weene LE . Ocular hypertension treatment study results could be misconstrued . [letter, comment] Arch Ophthalmol . 2003;121:1070
  38. Mansberger SL . A risk calculator to determine the probability of glaucoma . J Glaucoma . 2004;13:345–347
  39. Medeiros FA , Weinrab RN , Sample PA , et al.   Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma . Arch Ophthalmol . 2005;123:1351–1360
  40. Friedman DS , Wilson MR , Liebmann JM , Fechtner RD , Weinrab RN . An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma . Am J Ophthalmol . 2004;138:S19–S31
  41. Higginbotham EJ , Gordon MO , Beiser JA , et al.   The Ocular Hypertension Treatment Study (topical medication delays or prevents primary open-angle glaucoma in African-American individuals) . Arch Ophthalmol . 2004;122:813–820
  42. Leske MC , Connell AMS , Wu S-Y , et al.   Incidence of open-angle glaucoma (The Barbados Eye Study) . Arch Ophthalmol . 2001;119:89–95
  43. Mukesh BN , McCarty CA , Rait JL , Taylor HR . Five-year incidence of open-angle glaucoma . Ophthalmology . 2002;109:1047–1051
  44. Revicki DA , Frank L . Pharmacoeconomic evaluation in the real world (effectiveness versus efficacy studies) . Pharmacoeconomics . 1999;15:423–434
  45. Weiss NS . Clinical epidemiology (the study of the outcome of illness) . 2nd ed.. New York: Oxford University Press; 1996;
  46. Jampel HD , Schwartz GF , Robin AL , Abrams DA , Johnson E , Miller RB . Patient preferences for eye drop characteristics . Arch Ophthalmol . 2003;121:540–546
  47. Lee DJ , Gomez-Marin O , Lam BL , Zheng DD . Glaucoma and survival . Ophthalmology . 2003;110:1476–1483
  48. Age-related Eye Disease Study Group . Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study . Arch Ophthalmol . 2004;122:716–726
  49. Leske MC . Glaucoma and mortality (a connection) . [guest editorial] Ophthalmology . 2003;110:1473–1475
  50. McCarty CA , Nanjan M , Taylor HR . Vision impairment predicts five year mortality . Br J Ophthalmol . 2001;85:322–326
  51. Hattenhauer MG , Johnson DH , Ing HH , et al.   The probability of blindness from open-angle glaucoma . Ophthalmology . 1998;105:2099–2104
  52. Anderson RN . Method for constructing complete annual US life tables (vital and health statistics) . Hyattsville (MD): National Center for Health Statistics; 1999;
  53. Lairson DR , Begley CG , Reynolds TF , Wilhemus KR . Prevention of herpes simplex virus eye disease . Arch Ophthalmol . 2003;121:108–112

 Supplemental Material available at AJO.com.Supported by Awards to the Washington University School of Medicine Department of Ophthalmology and Visual Sciences from the National Eye Institute, the National Center on Minority Health and Health Disparities, National Institutes of Health (grants EY09341 and EY09307), and unrestricted grants from Merck Research Laboratories and Pfizer, Inc; and by Awards to the Washington University Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness, Inc, and the National Institutes of Health (P30 EY 02687) Core grant.For a complete list of OHTS investigators, please see the OHTS website at https://vrcc.wustl.edu

PII: S0002-9394(06)00039-0

doi: 10.1016/j.ajo.2006.01.019

American Journal of Ophthalmology
Volume 141, Issue 6 , Pages 997-1008.e3 , June 2006

Article Tools

* Image Usage & Resolution